Wachovia Downgrades Nabi Biopharmaceuticals

Analyst Martin Auster says there is less favorable risk/reward ahead of Phase III StaphVAX trial in late third quarter to early fourth quarter

Wachovia downgraded Nabi Biopharmaceuticals (NABI ) to market perform from outperform.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.